Nafloxin (Ciprofloxacin Hydrochloride)

Ciprofloxacin hydrochloride inhibits bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. By blocking these targets, the drug prevents bacterial cell division, leading to a bactericidal effect that clears the infection in the eye.

The dosing regimen for Nafloxin is determined by the prescribing clinician based on the severity of the infection, patient age, and response to therapy. The prescriber will specify the number of drops, frequency, and duration appropriate for each individual case.

The safety of Nafloxin (ciprofloxacin hydrochloride) in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh the potential benefits against possible risks and consider alternative treatments when safer options are available.

To order Nafloxin, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Nafloxin (ciprofloxacin) belongs to the fluoroquinolone class, offering broad‑spectrum coverage against Gram‑negative and some Gram‑positive ocular pathogens. Compared with older agents such as chloramphenicol or sulfonamides, ciprofloxacin generally provides faster bacterial eradication and a lower risk of resistance, though local susceptibility patterns should guide selection.

Nafloxin should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and discard any solution that appears discolored or contains particles.

Nafloxin is applied topically to the eye as directed by the prescriber. Typically, a few drops are placed in the affected eye(s) at the prescribed frequency, ensuring the eyelids are gently closed for a short period to allow adequate absorption.

Serious risks, though rare, include severe allergic reactions such as Stevens‑Johnson syndrome, corneal ulceration or perforation, and systemic tendon rupture. Patients should seek immediate medical attention if they experience intense pain, vision changes, swelling, or signs of a severe hypersensitivity reaction.

Nafloxin should not be used by individuals with a known hypersensitivity to ciprofloxacin, other fluoroquinolones, or any component of the ophthalmic formulation. It is also contraindicated for viral, fungal, or allergic eye conditions where an antibacterial agent would be ineffective.